Vaxil Bio Ltd., of Ness-Ziona, Israel, said it intends to complete a nonbrokered private placement of up to 25 million common shares at CA4 cents per share for gross proceeds of up to CA$750,000 (US$568,372), which are intended to be used to advance clinical programs, including formulation, in vitro screening and efficacy testing.